For: | Ke Y, Wang L, Li LQ, Zhong JH. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. World J Hepatol 2014; 6(9): 652-659 [PMID: 25276281 DOI: 10.4254/wjh.v6.i9.652] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v6/i9/652.htm |
Number | Citing Articles |
1 |
CHAOHUI ZUO, MAN XIA, QUNFENG WU, HAIZHEN ZHU, JINGSHI LIU, CHEN LIU. Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (Review). Oncology Letters 2015; 9(2): 527 doi: 10.3892/ol.2014.2727
|
2 |
Qin Wei, Huan Tian, Huan-xian Luo, Ying-cai Zhang, Yi-nan Deng, Jia Yao, Hua Li, Gui-hua Chen, Yang Yang. Better prognosis of hepatic resection combined with antiviral therapy for HBV-related hepatocellular carcinoma with BCLC Stage B/C. Asian Journal of Surgery 2017; 40(6): 453 doi: 10.1016/j.asjsur.2016.03.001
|
3 |
Wenqian Qi, Qian Zhang, Yan Xu, Xu Wang, Fan Yu, Yonggui Zhang, Ping Zhao, Honghua Guo, Changyu Zhou, Zhe Wang, Yu Sun, Lin Liu, Wei Xuan, Jiangbin Wang. Peg‐interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti‐HBV efficacy and long‐term survival among HBV DNA‐positive hepatocellular carcinoma patients after hepatectomy/ablation. Journal of Viral Hepatitis 2020; 27(4): 387 doi: 10.1111/jvh.13236
|
4 |
Shuqi Mao, Yuying Shan, Xi Yu, Jing Huang, Jiongze Fang, Min Wang, Rui Fan, Shengdong Wu, Caide Lu. A new prognostic model predicting hepatocellular carcinoma early recurrence in patients with microvascular invasion who received postoperative adjuvant transcatheter arterial chemoembolization. European Journal of Surgical Oncology 2023; 49(1): 129 doi: 10.1016/j.ejso.2022.08.013
|
5 |
Xiang Kui, Yan Wang, Cheng Zhang, Hai Li, Qingfeng Li, Yang Ke, Lin Wang. Prognostic value of SH3PXD2B (Tks4) in human hepatocellular carcinoma: a combined multi-omics and experimental study. BMC Medical Genomics 2021; 14(1) doi: 10.1186/s12920-021-00963-6
|
6 |
S. K. Sarin, M. Kumar, G. K. Lau, Z. Abbas, H. L. Y. Chan, C. J. Chen, D. S. Chen, H. L. Chen, P. J. Chen, R. N. Chien, A. K. Dokmeci, Ed Gane, J. L. Hou, W. Jafri, J. Jia, J. H. Kim, C. L. Lai, H. C. Lee, S. G. Lim, C. J. Liu, S. Locarnini, M. Al Mahtab, R. Mohamed, M. Omata, J. Park, T. Piratvisuth, B. C. Sharma, J. Sollano, F. S. Wang, L. Wei, M. F. Yuen, S. S. Zheng, J. H. Kao. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatology International 2016; 10(1): 1 doi: 10.1007/s12072-015-9675-4
|
7 |
Jian-Hong Zhong. Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. Tumor Biology 2014; 35(12): 12779 doi: 10.1007/s13277-014-2881-1
|
8 |
Chia-Chi Wang, Jia-Horng Kao. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?. Expert Opinion on Pharmacotherapy 2016; 17(7): 911 doi: 10.1517/14656566.2016.1149165
|
9 |
Sivesh K. Kamarajah. Fibrosis score impacts survival following resection for hepatocellular carcinoma (HCC): A Surveillance, End Results and Epidemiology (SEER) database analysis. Asian Journal of Surgery 2018; 41(6): 551 doi: 10.1016/j.asjsur.2018.01.001
|
10 |
Peng Yuan, Peng Chen, Yeben Qian. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology 2016; 2016: 1 doi: 10.1155/2016/5234969
|